KEY INFORMATION RELATING TO THE PROPOSED UNDERWRITTEN RIGHTS ISSUE IN PCI BIOTECH HOLDING ASA

Reference is made to the Company's announcement on 17 November 2016 regarding a
underwritten rights issue proposed resolved at an extraordinary general meeting
on 8 December 2016. The rights issue is subject to shareholder approval and a
prospectus approved by the Norwegian Financial Supervisory Authority and
published by the Company.

Key information in relation to the proposed rights issue:
Date on which the proposed terms and conditions of the rights issue were
announced: 17 November 2016
Last day including right: 8 December 2016
Ex-date: 9 December 2016
Record date: 12 December 2016
Date of approval: Not yet approved. Proposed that the extraordinary general
meeting to be held at 8 December 2016 approves the rights issue
Maximum number of new shares: 10,000,000 new shares
Subscription price per share: NOK 7

This information is published in accordance with the requirements of Continuing
Obligations of stock exchange listed companies.

For more information visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379
Oslo
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.